跳至主要内容
临床试验/2022-500389-84-00
2022-500389-84-00招募中4 期

SAFE study: Stopping Antibiotics after 3 days for the treatment of FEbrile Neutropenia in Haematology patients, a randomized open-label non-inferiority trial

UZ Leuven9 个研究点 分布在 1 个国家目标入组 410 人开始时间: 2023年8月23日最近更新:

试验速览

阶段
4 期
状态
招募中
发起方
UZ Leuven
入组人数
410
试验地点
9
主要终点
Absence of a serious medical complication (SMC) following 42 days after randomisation. SMC is defined as: Death; and/or ICU admission; and/or Septic shock requiring vasopressive therapy.

研究概览

简要总结

To assess if a strategy of short antibiotic treatment (72h) with a broad-spectrum antibiotic is as safe as extended treatment of high-risk febrile neutropenia in hematology patients.

入排标准

年龄范围
18 years 至 65+ years(65+ Years, 18-64 Years)
接受健康志愿者

入选标准

  • Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures
  • Age older than 16 years
  • Intensive therapy is started within three days before randomization for one of the following haematological conditions: Remission induction chemotherapy for newly diagnosed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); OR Re-induction chemotherapy for relapsed after haematological remission lasting for a minimum duration of 6 months; OR Conditioning regimen to prepare for an allogeneic HCT; OR Conditioning regimen to prepare for an autologous HCT.
  • Expected longstanding (≥ 7 days) neutropenia (absolute neutrophil count < 0.5x10^9/L)
  • Expected length of hospital stay of at least 10 days

排除标准

  • Clinically or microbiologically documented infection
  • Patient already receives broad spectrum antibiotic therapy
  • Any critical illness for which Intensive Care Unit treatment is required
  • SOFA score ≥ 11
  • Longstanding neutropenia (>21 days) prior inclusion
  • Previous enrolment in this study
  • Not able to provide written informed consent
  • Any disorder, which in the Investigator’s opinion might jeopardise the participant’s safety or compliance with the protocol
  • Any prior or concomitant treatment(s) that might jeopardise the participant’s safety or that would compromise the integrity of the Trial

结局指标

主要结局

Absence of a serious medical complication (SMC) following 42 days after randomisation. SMC is defined as: Death; and/or ICU admission; and/or Septic shock requiring vasopressive therapy.

Absence of a serious medical complication (SMC) following 42 days after randomisation. SMC is defined as: Death; and/or ICU admission; and/or Septic shock requiring vasopressive therapy.

次要结局

  • Incidence of bacteraemia within 42 days after randomisation
  • Clinically documented infections
  • Number of documented bacterial infections
  • Total days of non-prophylactic antibiotics given to the patient at engraftment
  • Total numbers of antibiotic switches before neutrophil recovery
  • Incidence of Clostridium difficile infection
  • Incidence, severity and duration of diarrhea
  • Incidence of candidemia
  • Length of hospital stay in the first 42 days after randomization
  • Number of patients admitted to the ICU within 42 days after randomisation
  • Number of readmissions within 42 days
  • Number of patients with a culture (surveillance or diagnostic culture) positive for resistant bacteria: VRE; ESBL; MRSA; and/or CPE
  • Duration of hospitalization
  • Number of patients in the short treatment arm with ongoing fever at time of EBAT stop
  • Incidence of acute GVHD (grade II or higher) in the transplanted study population

研究者

发起方
UZ Leuven
申办方类型
Hospital/Clinic/Other health care facility
责任方
Principal Investigator
主要研究者

Robina Aerts

Scientific

UZ Leuven

研究点 (9)

Loading locations...

相似试验